Mustang Bio, Inc. (MBIO) Key Metrics
MBIO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.9M
- Enterprise value
- −$13.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.5 10-yr median 101.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.09
MBIO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMBIO valuation Price multiples at each fiscal year-end price.
Price / book
0.5
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−88.3 pts
−109.3%
2025 · hover or tap a bar for each year
20162025
MBIO returns How much profit the business earns on the capital it uses.
Return on equity
−67.9%
2025 · hover or tap a bar for each year
20162025
Return on assets+102.2 pts
−14.3%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
MBIO per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.39
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.07
2025 · hover or tap a bar for each year
20162025
Book value per share
$1.94
2025 · hover or tap a bar for each year
20162025
Dividends per share−44.2%
$0.06
2025 · hover or tap a bar for each year
20162025
Shares outstanding−19.9%
4.9M
2025 · hover or tap a bar for each year
20162025
MBIO financial health Debt, liquidity and how easily interest is covered.
Net debt−$11.3M
−$17.3M
2025 · hover or tap a bar for each year
20162025
Current ratio+225.7%
2.22
2025 · hover or tap a bar for each year
20162025
MBIO efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+45,791 days
48,848 days
2025 · hover or tap a bar for each year
20162025
MBIO valuation history
Fiscal year-endToday10-year median
MBIO returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MBIO debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MBIO cash returned to shareholders
DividendsBuybacksFree cash flow
MBIO price vs earnings per share
Share price at year-endEPS (right axis)
MBIO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.8M | $54.2M | $580.8M | $2.04B | $7.29B | $9.95B | $7.36B | $3.96B | $15.14B | — |
| Enterprise value | −$12.5M | $48.3M | $577.0M | $2.00B | $7.19B | $9.86B | $7.31B | $3.93B | $15.08B | — |
| Price / book | 0.5 | — | — | 44.1 | 64.9 | 101.1 | 142.4 | 108.8 | 253.0 | — |
| Earnings yield | −39.9% | −29.0% | −8.9% | −3.8% | −0.9% | −0.6% | −0.7% | −0.8% | −0.2% | — |
| Free cash flow yield | −109.3% | −21.0% | −8.5% | −3.3% | −0.8% | −0.4% | −0.5% | −0.7% | −0.1% | — |
| Dividend yield | 5.7% | 1.1% | 0.1% | — | — | — | — | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | 5.7% | 1.1% | 0.1% | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Share price at fiscal year-end | $0.98 | $8.85 | $67.50 | $296.18 | $1,245.00 | $2,838.75 | $3,060.00 | $2,205.00 | $8,992.50 | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.39 | −$2.57 | −$6.00 | −$11.24 | −$11.33 | −$17.12 | −$20.03 | −$17.07 | −$18.58 | −$7.24 |
| Operating cash flow per share | −$1.07 | −$1.86 | −$5.75 | −$9.44 | −$9.16 | −$10.64 | −$13.97 | −$10.71 | −$7.69 | −$2.36 |
| Free cash flow per share | −$1.07 | −$1.86 | −$5.76 | −$9.88 | −$10.08 | −$11.90 | −$15.51 | −$15.13 | −$9.35 | −$2.36 |
| Cash per share | $3.52 | $1.12 | $0.72 | $10.97 | $18.71 | $27.90 | $25.54 | $18.97 | $36.22 | $15.72 |
| Book value per share | $1.94 | −$0.63 | $0.01 | $6.71 | $19.18 | $28.08 | $21.48 | $20.26 | $35.54 | $13.88 |
| Tangible book value per share | $1.94 | −$0.63 | $0.01 | $6.71 | $19.18 | $28.08 | $21.48 | $20.26 | $35.54 | $13.88 |
| Dividends per share | $0.06 | $0.10 | $0.06 | — | — | — | — | — | $0.19 | $0.00 |
| Capex per share | $0.00 | $0.00 | $0.01 | $0.45 | $0.92 | $1.26 | $1.54 | $4.42 | $1.66 | $0.24 |
| Debt per share | — | $0.14 | $0.29 | $4.55 | $0.35 | $0.64 | $6.46 | — | $0.00 | $0.18 |
| Shares outstanding | 4.9M | 6.1M | 8.6M | 6.9M | 5.9M | 3.5M | 2.4M | 1.8M | 1.7M | 1.7M |
| Change in shares outstanding | −19.9% | −28.8% | +24.8% | +17.7% | +67.1% | +45.8% | +33.8% | +6.7% | −3.7% | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −67.9% | — | −222.4% | −97.7% | −63.0% | −80.0% | −109.4% | −63.7% | −74.4% | −125.6% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −896.0% | — | — | — |
| Return on assets (ROA) | −14.3% | −116.5% | −93.7% | −71.3% | −56.5% | −65.5% | −82.9% | −57.7% | −68.8% | −46.0% |
| Return on tangible assets | −10.9% | −169.2% | −290.8% | −83.9% | −53.0% | −54.6% | −65.6% | −71.7% | −49.3% | −46.0% |
| Financial health | ||||||||||
| Total debt | — | $878,000 | $2.5M | $31.4M | $2.0M | $2.2M | $15.5M | — | $0 | $320,000 |
| Cash & short-term investments | $17.3M | $6.8M | $6.2M | $75.7M | $109.6M | $97.8M | $61.4M | $34.1M | $61.0M | $27.5M |
| Net debt | −$17.3M | −$6.0M | −$3.7M | −$44.3M | −$107.6M | −$95.6M | −$45.9M | −$34.1M | −$61.0M | −$27.2M |
| Debt / equity | — | — | 20.31 | 0.68 | 0.02 | 0.02 | 0.30 | — | 0.00 | 0.01 |
| Debt / assets | — | 0.09 | 0.14 | 0.34 | 0.02 | 0.02 | 0.21 | — | 0.00 | 0.01 |
| Current ratio | 2.22 | 0.68 | 0.74 | 5.22 | 10.33 | 10.46 | 8.12 | 6.25 | 16.99 | 8.53 |
| Quick ratio | 2.22 | 0.68 | 0.74 | 5.22 | 10.33 | 10.46 | 8.12 | 6.25 | 16.99 | 8.53 |
| Interest coverage | — | — | -38.6 | -22.7 | — | -14.5 | -26.0 | — | — | 9.9 |
| Working capital | $9.7M | −$4.0M | −$4.0M | $63.7M | $100.9M | $90.0M | $55.3M | $29.5M | $57.8M | $24.3M |
| Invested capital | −$7.7M | −$9.8M | −$3.6M | $2.0M | $4.8M | $2.9M | $5.8M | $2.3M | −$1.1M | −$2.9M |
| Tangible asset value | $9.5M | −$3.9M | $123,000 | $46.3M | $112.4M | $98.4M | $51.7M | $36.4M | $59.8M | $24.3M |
| Net current asset value | $9.5M | −$4.6M | −$6.3M | $32.7M | $98.9M | $88.1M | $41.3M | $28.8M | $57.7M | $24.3M |
| Graham net-net per share | $1.91 | −$0.99 | −$0.99 | $4.31 | $16.54 | $24.63 | $16.49 | $15.44 | $34.09 | $13.88 |
| Capital allocation | ||||||||||
| Dividends paid | $273,000 | $611,000 | $477,000 | — | — | — | — | — | $320,000 | $0 |
| Share buybacks (net) | — | — | $0 | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | 0.00 | 0.00 | 0.05 | 1.02 | 2.33 | 2.47 | 2.70 | 12.61 | 1,399.50 | 212.00 |
| Efficiency | ||||||||||
| Days payables outstanding | 48,847.7 | 3,057.0 | 1,079.0 | 622.9 | 556.4 | 551.6 | 435.3 | 1,407.9 | 379,326.2 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Payables turnover | 0.01 | 0.12 | 0.34 | 0.59 | 0.66 | 0.66 | 0.84 | 0.26 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $309,500 | $2.1M | $2.1M | $174,500 | $32,500 | $17,000 | $28,000 | $71,500 | $106,000 | — |
| Average payables | $5.5M | $6.9M | $6.6M | $5.2M | $3.5M | $2.7M | $1.6M | $2.4M | $2.1M | $349,000 |
| Average inventory | — | — | — | — | — | — | — | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MBIO's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MBIO valuation and financial ratios
Mustang Bio earned a return on equity of −67.9% in fiscal 2025. It returned $0.3 million to shareholders: $0.3 million in dividends and $0 in share buybacks. The share count rose 180.7% from 1.7M to 4.9M over 9 years.
See the MBIO income statement, the MBIO chart for price history, or the MBIO stock overview for the latest quote and news.
MBIO key metrics FAQ
What is Mustang Bio's return on equity?
Mustang Bio's return on equity (ROE) was −67.9% in fiscal 2025: net income of -$1.9 million on average shareholders' equity of $2.8 million.
What is Mustang Bio's dividend yield?
Mustang Bio paid $0.3 million in dividends in fiscal 2025 ($0.06 per share), a payout ratio of —.
What is Mustang Bio's free cash flow yield?
Mustang Bio generated -$5.3 million of free cash flow in fiscal 2025, a free cash flow yield of −109.3% on its market value at year-end ($4.8 million).
What is Mustang Bio's current ratio?
Mustang Bio's current ratio was 2.22 at the end of fiscal 2025: current assets were 2.22 times current liabilities.